Table of Contents
Chapter 1. Methodology and Scope
1.1 Market Segmentation and Scope
1.1.1 Segment Definitions
1.1.1.1 Dosage Type
1.1.1.2. Product
1.1.1.3. Application
1.2 Regional Scope
1.3 Estimates and Forecast Timeline
1.4 Objectives
1.4.1 Objective – 1
1.4.2 Objective – 2
1.4.3 Objective – 3
1.5 Research Methodology
1.6 Information Procurement
1.6.1 Purchased Database
1.6.2 Gvr’s Internal Database
1.6.3 Secondary Sources
1.6.4 Primary Research
1.7 Information Or Data Analysis
1.7.1 Data Analysis Models
1.8 Market Formulation & Validation
1.9 Model Details
1.9.1 Commodity Flow Analysis
1.10 List Of Secondary Sources
1.11 List of Abbreviations
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Dosage Type outlook
2.2.2. Product outlook
2.2.3. Application outlook
2.2.4. Regional outlook
2.3. Competitive Insights
Chapter 3. Brachytherapy Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Industry Value Chain Analysis
3.2.1. Reimbursement framework
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.1.1. The increasing prevalence of cancer
3.3.1.2. Technological advancements
3.3.2. Market restraint analysis
3.3.2.1. Lack of skilled radiotherapy professionals
3.4. Brachytherapy Market Analysis Tools
3.4.1. Industry Analysis – Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
3.4.3. Major Deals & Strategic Alliances Analysis
Chapter 4. Brachytherapy: Dosage Type Estimates & Trend Analysis
4.1. Definitions and Scope
4.1.1. High-Dose Rate (HDR)
4.1.2. Low-Dose Rate (LDR)
4.2. Dosage Type Market Share, 2022 & 2030
4.3. Segment Dashboard
4.4. Global Brachytherapy Market by Dosage Type Outlook
4.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.5.1. High-Dose Rate (HDR)
4.5.1.1. HDR market estimates and forecast 2018 to 2030 (USD Million)
4.5.2. Low-Dose Rate (LDR)
4.5.2.1. LDR market estimates and forecast 2018 to 2030 (USD Million)
Chapter 5. Brachytherapy: Product Estimates & Trend Analysis
5.1. Product Market Share, 2022 & 2030
5.2. Segment Dashboard
5.3. Global Brachytherapy Market by Material Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.4.1. Seeds
5.4.1.1. Seeds market estimates and forecast 2018 to 2030 (USD Million)
5.4.2. Applicators & Afterloaders
5.4.2.1. Applicators & Afterloaders market estimates and forecast 2018 to 2030 (USD Million)
5.4.3. Electronic brachytherapy
5.4.3.1. Electronic brachytherapy market estimates and forecast 2018 to 2030 (USD Million)
Chapter 6. Brachytherapy: Application Estimates & Trend Analysis
6.1. Application Market Share, 2022 & 2030
6.2. Segment Dashboard
6.3. Global Brachytherapy Market by Application Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.4.1. Prostrate
6.4.1.1. Prostrate market estimates and forecast 2018 to 2030 (USD Million)
6.4.2. Gynecological Cancer
6.4.2.1. Gynecological Cancer market estimates and forecast 2018 to 2030 (USD Million)
6.4.3. Breast
6.4.3.1. Breast management market estimates and forecast 2018 to 2030 (USD Million)
6.4.4. Others
6.4.4.1. Others market estimates and forecast 2018 to 2030 (USD Million)
Chapter 7. Brachytherapy Market: Regional Estimates & Trend Analysis
7.1. Regional market share analysis, 2022 & 2030
7.2. Regional Market Dashboard
7.3. Global Regional Market Snapshot
7.4. Regional Market Share and Leading Players, 2021
7.4.1. North America
7.4.2. Europe
7.4.3. Asia Pacific
7.4.4. Latin America
7.4.5. Middle East and Africa
7.5. SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
7.5.1. North America
7.5.2. Europe
7.5.3. Asia Pacific
7.5.4. Latin America
7.5.5. Middle East and Africa
7.6. Market Size, & Forecasts, Volume and Trend Analysis, 2018 to 2030:
7.7. North America
7.7.1. SWOT Analysis
7.7.2. North America Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
7.7.3. U.S.
7.7.3.1. Key Country Dynamics
7.7.3.2. Target Disease Prevalence
7.7.3.3. Competitive Scenario
7.7.3.4. Regulatory Framework
7.7.3.5. U.S. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
7.7.4. Canada
7.7.4.1. Key Country Dynamics
7.7.4.2. Target Disease Prevalence
7.7.4.3. Competitive Scenario
7.7.4.4. Regulatory Framework
7.7.4.5. Canada Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
7.8. Europe
7.8.1. SWOT Analysis
7.8.2. Europe Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
7.8.3. UK
7.8.3.1. Key Country Dynamics
7.8.3.2. Target Disease Prevalence
7.8.3.3. Competitive Scenario
7.8.3.4. Regulatory Framework
7.8.3.5. UK Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
7.8.4. Germany
7.8.4.1. Key Country Dynamics
7.8.4.2. Target Disease Prevalence
7.8.4.3. Competitive Scenario
7.8.4.4. Regulatory Framework
7.8.4.5. Germany Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
7.8.5. France
7.8.5.1. Key Country Dynamics
7.8.5.2. Target Disease Prevalence
7.8.5.3. Competitive Scenario
7.8.5.4. Regulatory Framework
7.8.5.5. France Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
7.8.6. Italy
7.8.6.1. Key Country Dynamics
7.8.6.2. Target Disease Prevalence
7.8.6.3. Competitive Scenario
7.8.6.4. Regulatory Framework
7.8.6.5. Italy Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
7.8.7. Spain
7.8.7.1. Key Country Dynamics
7.8.7.2. Target Disease Prevalence
7.8.7.3. Competitive Scenario
7.8.7.4. Regulatory Framework
7.8.7.5. Spain Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
7.8.8. Denmark
7.8.8.1. Key Country Dynamics
7.8.8.2. Target Disease Prevalence
7.8.8.3. Competitive Scenario
7.8.8.4. Regulatory Framework
7.8.8.5. Denmark Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
7.8.9. Sweden
7.8.9.1. Key Country Dynamics
7.8.9.2. Target Disease Prevalence
7.8.9.3. Competitive Scenario
7.8.9.4. Regulatory Framework
7.8.9.5. Sweden Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
7.8.10. Norway
7.8.10.1. Key Country Dynamics
7.8.10.2. Target Disease Prevalence
7.8.10.3. Competitive Scenario
7.8.10.4. Regulatory Framework
7.8.10.5. Norway Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
7.9. Asia Pacific
7.9.1. SWOT Analysis
7.9.2. Asia Pacific Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
7.9.3. China
7.9.3.1. Key Country Dynamics
7.9.3.2. Target Disease Prevalence
7.9.3.3. Competitive Scenario
7.9.3.4. Regulatory Framework
7.9.3.5. China Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
7.9.4. Japan
7.9.4.1. Key Country Dynamics
7.9.4.2. Target Disease Prevalence
7.9.4.3. Competitive Scenario
7.9.4.4. Regulatory Framework
7.9.4.5. Japan Market estimates and forecast, 2018 – 2030 (Volume, Thousand)
7.9.5. India
7.9.5.1. Key Country Dynamics
7.9.5.2. Target Disease Prevalence
7.9.5.3. Competitive Scenario
7.9.5.4. Regulatory Framework
7.9.5.5. India Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
7.9.6. Australia
7.9.6.1. Key Country Dynamics
7.9.6.2. Target Disease Prevalence
7.9.6.3. Competitive Scenario
7.9.6.4. Regulatory Framework
7.9.6.5. Australia Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
7.9.7. Thailand
7.9.7.1. Key Country Dynamics
7.9.7.2. Target Disease Prevalence
7.9.7.3. Competitive Scenario
7.9.7.4. Regulatory Framework
7.9.7.5. Thailand Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
7.9.8. South Korea
7.9.8.1. Key Country Dynamics
7.9.8.2. Target Disease Prevalence
7.9.8.3. Competitive Scenario
7.9.8.4. Regulatory Framework
7.9.8.5. South Korea Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
7.10. Latin America
7.10.1. SWOT Analysis
7.10.2. Latin America Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
7.10.3. Brazil
7.10.3.1. Key Country Dynamics
7.10.3.2. Target Disease Prevalence
7.10.3.3. Competitive Scenario
7.10.3.4. Regulatory Framework
7.10.3.5. Brazil Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
7.10.4. Mexico
7.10.4.1. Key Country Dynamics
7.10.4.2. Target Disease Prevalence
7.10.4.3. Competitive Scenario
7.10.4.4. Regulatory Framework
7.10.4.5. Mexico Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
7.10.5. Argentina
7.10.5.1. Key Country Dynamics
7.10.5.2. Target Disease Prevalence
7.10.5.3. Competitive Scenario
7.10.5.4. Regulatory Framework
7.10.5.5. Argentina Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
7.11. MEA
7.11.1. SWOT Analysis
7.11.2. MEA Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
7.11.3. Saudi Arabia
7.11.3.1. Key Country Dynamics
7.11.3.2. Target Disease Prevalence
7.11.3.3. Competitive Scenario
7.11.3.4. Regulatory Framework
7.11.3.5. Saudi Arabia Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
7.11.4. South Africa
7.11.4.1. Key Country Dynamics
7.11.4.2. Target Disease Prevalence
7.11.4.3. Competitive Scenario
7.11.4.4. Regulatory Framework
7.11.4.5. South Africa Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
7.11.5. UAE
7.11.5.1. Key Country Dynamics
7.11.5.2. Target Disease Prevalence
7.11.5.3. Competitive Scenario
7.11.5.4. Regulatory Framework
7.11.5.5. UAE Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
7.11.6. Kuwait
7.11.6.1. Key Country Dynamics
7.11.6.2. Target Disease Prevalence
7.11.6.3. Competitive Scenario
7.11.6.4. Regulatory Framework
7.11.6.5. Kuwait Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.2.1. Innovators
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.3.3. Key company market share analysis, 2021
8.3.4. ECKERT & ZIEGLER BEBIG
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.5. ISORAY MEDICAL, INC.
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Product benchmarking
8.3.5.4. Strategic initiatives
8.3.6. ELEKTA AB
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Product benchmarking
8.3.6.4. Strategic initiatives
8.3.7. THERAGENICS
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Product benchmarking
8.3.7.4. Strategic initiatives
8.3.8. Becton, Dickinson, and Company
8.3.8.1. Company overview
8.3.8.2. Financial performance
8.3.8.3. Product benchmarking
8.3.8.4. Strategic initiatives
8.3.9. CIVCO MEDICAL SOLUTIONS
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Product benchmarking
8.3.9.4. Strategic initiatives
8.3.10. SUN NUCLEAR CORPORATION
8.3.10.1. Company overview
8.3.10.2. Financial performance
8.3.10.3. Product benchmarking
8.3.10.4. Strategic initiatives
8.3.11. ICAD, INC.
8.3.11.1. Company overview
8.3.11.2. Financial performance
8.3.11.3. Product benchmarking
8.3.11.4. Strategic initiatives
8.3.12. VARIAN MEDICAL SYSTEMS, INC.
8.3.12.1. Company overview
8.3.12.2. Financial performance
8.3.12.3. Product benchmarking
8.3.12.4. Strategic initiatives
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/